Company

Noam Solomon, PhD

CEO & Co-Founder

Noam Solomon is the CEO and co-founder at Immunai, the first company set to decode the immune system for better detection, diagnosis, and treatment of disease, and discovery of novel therapeutics.

Prior to co-founding Immunai, Noam had a dual career in both industry and academia. Noam has a double Ph.D., in Math and Computer Science, and served as a post-doctoral researcher in the Mathematics department at the Massachusetts Institute of Technology, and in the Center of Mathematical Sciences and Applications at Harvard University.

Noam also worked as an algorithms developer and a data scientist, consultant, and head of data science in several hi-tech companies in Israel.

Daniel Cohen

COO

Daniel Cohen, Chief Operating Officer at Immunai, drives product strategy, operations, and delivery to ensure efficiency and effectiveness across all departments. Daniel leads cross-functional teams to align company objectives, processes, and deliverables with the overarching business strategy.

Prior to Immunai, Daniel was Chief Operating Officer at Trax, and a key player in the company evolution from inception to a $2.5B valuation, overseeing expansion from a single client to a portfolio of over 600 clients, while scaling annual recurring revenue from zero to $165M.

Before Trax, Daniel led PrimeSense’s core 3D mapping technology, successfully supporting Microsoft Kinect in becoming the fastest-selling consumer device with over 8M units sold in the first two months. PrimeSense was later acquired by Apple for $360M.

Daniel holds an MBA from Tel Aviv University and both a B.Sc. and M.Sc. in Electrical and Computer Engineering from Ben-Gurion University.

Tali Raveh-Sadka, PhD

VP, R&D

Tali Raveh-Sadka, Immunai’s Vice President of R&D, holds a PhD in Computational Biology from the Weizmann Institute of Science and completed her postdoc at the University of California, Berkeley. Prior to joining Immunai, Tali was the Director of Research at DayTwo.

Sen Zhang

VP, Product

Sen joined Immunai as Vice President of Product Management in 2020. Prior to Immunai, Sen led business and technology product initiatives at Two Sigma Investments, Flatiron Health, and Palantir. Sen studied Biology and Economics at Dartmouth College, and lives in NYC with his wife and three kids.

Adeeb Rahman, PhD

VP, Platform Architecture

Adeeb Rahman, Immunai’s VP of Platform Architecture, joined Immunai after nearly a decade in a variety of roles at the Icahn School of Medicine at Mount Sinai.

Most recently, Adeeb was an Associate Professor in the Department of Genetics and Genomic Sciences, a member of the Precision Immunology Institute and Tisch Cancer Institute and served as the Director of Technology Development for the Human Immune Monitoring Center.

In that role, he led a team of wet bench and computational scientists focused on developing and optimizing high-dimensional cytometry and multi-modal single-cell immunological assays, and collaboratively applying them across a wide range of basic, translational and clinical research projects.

His lab also served as a central hub for several multi-institutional academic and industry collaborations including the NIH Human Immunology Project Consortium (HIPC), the CZI Seed Networks for the Human Cell Atlas (HCA), the NCI Cancer Immune Monitoring and Analysis Centers (CIMAC) and the Partnership for Accelerating Cancer Therapies (PACT).

Adeeb earned his Bachelor of Science in Biology from Brown University and his PhD in Immunology from the University of Pennsylvania School of Medicine and completed postdoctoral fellowships at the University of North Carolina, Chapel Hill and the Icahn School of Medicine at Mt. Sinai. He lives in New York City with his wife and two daughters.

Evan Zisholtz

VP, Global BD

Evan is Vice President of Global Business Development at Immunai, and oversees both BD and M&A. Prior to Immunai, Evan supported M&A and Corporate Strategy at Lonza. Evan began his career as an attorney in private practice in New York and holds a JD from New York University School of Law.

Roy Cohen

VP, Finance

Roy is Vice President of Finance at Immunai. He oversees finance, legal and long-term strategic planning. Roy has over 17 years of financial management experience in publicly traded tech companies. He has a strong track record of supporting company growth, implementing major processes and tools, and building long term financial strategy. Roy joined Immunai from Kornit Digital where he started as Director of FP&A, overseeing financial planning, compensation & benefits, and risk management, and was promoted to VP Finance and then to VP Aftermarket Business where he oversaw a $140m business unit. Roy holds a bachelor’s degree in Economics & Management and an MBA from Bar-Ilan University.

Elisha Nathan, PhD

VP, Commercial

Elisha Nathan, VP Commercial at Immunai, holds a PhD in Molecular Biology from the Weizmann Institute of Science and an MBA from Bar-Ilan University. Prior to joining Immunai, Elisha was the VP Strategic Alliances at CytoReason and served as the Director of Business Development at Evogene (Nasdaq: EVGN) and Protalix (NYSE :PLX).

Galit Yahalom, PhD

VP, Operations

Galit Yahalom, VP Operations at Immunai, joined the company after an extensive career in the biotechnology industry. Prior to joining Immunai, she served as VP Clinical, Laboratory and Regulatory Affairs at Oncohost, COO of Eventus Dx, and a consultant in the industry.

Galit holds a PhD in Molecular Biology from the Weizmann Institute of Science, and lives in Modiin with her husband and two kids.

Ronit Weinstein

VP, Human Resources

Ronit Weinstein, VP Human Resources at Immunai, has over 30 years of experience in the human resources and organizational development space. She has built successful HR teams and infrastructure for various companies in domains as diverse as telecommunications (Flash Networks, ECI, Allot, TTI), cybersecurity (Allot, Verint), and biotechnology (Compugen, Immunai), both in small startups and well-established companies. She is an experienced coach and mentor, and focuses on connecting people to each other and the business. This is her 8th role as a VP HR.
Ronit has a BA degree in Sociology and Political Science from Tel Aviv University and a Master’s degree in Sociology from UCLA.

Robert S. Langer, PhD

Board member

Dr. Robert Langer serves on Immunai’s Board of Directors. Bob is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. Bob is also a faculty member of the Harvard-MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research.

Langer holds over 1,400 granted or pending patents and is one of the world’s most highly cited researchers. His h-index is 301 with over 365,000+ citations. He is widely recognized in biotechnology, especially in the fields of drug delivery systems and tissue engineering. Bob is also a prolific entrepreneur and participated in the founding of over 40 biotechnology companies, including Moderna. Langer’s research laboratory at MIT is the largest biomedical engineering lab in the world; maintaining over $10 million in annual grants and over 100 researchers. He has been awarded numerous leading prizes in recognition of his work.

Mikael Dolsten, MD, PhD

Board member

Mikael Dolsten is the former Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, Inc. in that role he lead a team of over 8,000 scientists and did oversee all global research operations across six therapeutic areas. He brings over twenty-five years of Pharma experience leading teams that have selected more than 150 candidate drugs for the treatment of human disease and advanced möre than 40 NME candidate drugs towards late-stage development drugs through registration and successful drug approvals . Under Mikael’s leadership, Pfizer has, as of year end 2025, achieved more than 35 approvals of which more than half are New Medical Entities (NME), ranging from therapies for rheumatoid arthritis, stroke prevention and cancer to a pneumococcal vaccine.

Mikael received his medical degree and doctorate from Lund University in Sweden where he was also appointed as Adjunct Professor in Tumor Immunology. He has published some 160 scientific original articles and book reviews. Mikael is an active leader in the scientific community, currently serving as a fellow of the New York Academy of Medicine. Mikael served on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA), the PhRMA Foundation Board of Directors. In addition, Mikael was elected as Foreign Member of The Royal Swedish Academy of Engineering Sciences. – and a member of several other healthcare & science organizations
He is a board member of Agilent Technologies, Rocket Pharma , ImmuneAI, Fair Journey Biologics and chairman of the board of Orbis Medicines and Quarry Thera Biotech. Mikael is a senior advisor to Blackstone , Formation Bio and ChAi Discovery Biotech.

Stanley Frankel, MD

Dr. Stanley R. Frankel (M.D.) is Adjunct Professor of Medicine at the Division of Hematology/Oncology at Columbia University’s Vagelos College of Physicians and Surgeons, and Consultant to the world’s most innovative companies developing immuno-oncology and cellular therapies, drugs and compounds. Dr. Frankel sits on the Board of Directors and the Science and Technology Committee of Precision BioSciences, Inc. where he supports the development, approval and commercial deployment of advanced gene correction therapies.

Dr. Frankel is a leading academic and industry expert in the research, clinical development, and commercialization of cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.

Dr. Frankel has held the highest executive and leadership positions at Bristol-Myers Squibb (BMS), Celgene, Merck, AMGEN, Hoffmann-LA Roche, and others; he has also served on steering/development committees with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene.

Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency at Mount Sinai Hospital and his fellowship at Memorial Sloan Kettering Cancer Center, where he was Chief Fellow. Frankel has held academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland.

Ansuman Satpathy, MD, PhD

Scientific Co-Founder

Dr. Ansuman Satpathy M.D., Ph.D. is an Assistant Professor in the Department of Pathology at Stanford University School of Medicine and a Scientific Co-Founder of Immunai. He is an investigator in the Gladstone-UCSF Institute of Genomic Immunology, the Parker Institute for Cancer Immunotherapy, and the Stanford Cancer Institute.

Dr. Satpathy has pioneered the development and use of high-throughput genome sequencing technologies to study cancer immunology. His work has led to fundamental insights into how T cells – the cancer killing immune cell in the body – recognize and respond to cancer antigens and various forms of cancer immunotherapy. Dr. Satpathy’s honors include the Pew-Stewart Scholar Award in Cancer Research, the Lloyd J. Old STAR Award from the Cancer Research Institute, the Career Award for Medical Scientists from the Burroughs Wellcome Fund, and the Michelson Prize in Human Immunology.

Dr. Satpathy completed an M.D. and Ph.D. in immunology at Washington University in St. Louis, clinical residency in pathology at Stanford Hospital and Clinics, and postdoctoral training in genetics at Stanford University.

Regina Barzilay, PhD

Dr. Regina Barzilay is a School of Engineering Distinguished Professor for AI and Health in the Department of Electrical Engineering and Computer Science and a member of the Computer Science and Artificial Intelligence Laboratory at the Massachusetts Institute of Technology. She is an AI faculty lead for Jameel Clinic, an MIT center for Machine Learning in Health.

Her research interests are in natural language processing and applications of deep learning to chemistry and oncology. She is a recipient of various awards including the NSF Career Award, the MIT Technology Review TR-35 Award, Microsoft Faculty Fellowship and several Best Paper Awards at NAACL and ACL. In 2017, she received a MacArthur fellowship, an ACL fellowship and an AAAI fellowship. In 2020, she was awarded the Squirrel AI Award for Artificial Intelligence for the Benefit of Humanity.

She received her PhD in Computer Science from Columbia University, and spent a year as a postdoc at Cornell University. Prof. Barzilay received her undergraduate degree from Ben-Gurion University of the Negev, Israel.

Caroline Uhler, PhD

Dr. Caroline Uhler co-directs the Eric and Wendy Schmidt Center at the Broad Institute. She is also Associate Professor in the Department of Electrical Engineering and Computer Science and the Institute for Data, Systems, and Society at MIT.

Uhler develops machine learning methods for integrating and translating between vastly different data modalities and inferring causal or regulatory relationships from such data. She is particularly interested in using these methods to gain mechanistic insights into the link between genome packing and regulation in health and disease.

Uhler is recognized as a creative and innovative researcher at the intersection of machine learning, statistics, and biology. She has received multiple prestigious career prizes including a Simons Investigator Award, a Sloan Research Fellowship, a Sofja Kovalevskaja Award, and an NSF Career Award.

Uhler holds an M.Sc. in mathematics, a B.Sc. in biology, and an M.Ed., all from the University of Zurich. She obtained her Ph.D. in statistics from UC Berkeley in 2011 and then spent three years as an assistant professor at IST Austria before joining the faculty at MIT.

Prof. Ido Amit

Ido Amit is a Professor at the Immunology Department at the Weizmann Institute of Science and HHMI International Research Scholar. His lab has led and pioneered the development of single-cell genomics and its application to the characterization of the immune system. His research using these technologies has revolutionized our understanding of the immune system, identifying dozens of new immune subsets. His technologies and discoveries are enabling the development of novel immunotherapy strategies, which he utilized for the development of the next generation of immunotherapy treatments. His international profile as one of the leaders of the immuno-genomics field is demonstrated by numerous impactful papers in leading journals, a large number of excellence prizes, a strong track record of external funding, advisory positions, and company formation.

By the Numbers:

Funding

Founded

Team members

Locations

Partnerships